GRI Bio (GRI) Competitors $1.51 -0.02 (-1.31%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. REVB, PALI, IMCC, ARAV, MTNB, SNPX, AWH, RDHL, ONVO, and ENSCShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Revelation Biosciences (REVB), Palisade Bio (PALI), IM Cannabis (IMCC), Aravive (ARAV), Matinas Biopharma (MTNB), Synaptogenix (SNPX), Aspira Women's Health (AWH), RedHill Biopharma (RDHL), Organovo (ONVO), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Revelation Biosciences Palisade Bio IM Cannabis Aravive Matinas Biopharma Synaptogenix Aspira Women's Health RedHill Biopharma Organovo Ensysce Biosciences Revelation Biosciences (NASDAQ:REVB) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Does the MarketBeat Community prefer REVB or GRI? Revelation Biosciences received 26 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote. CompanyUnderperformOutperformRevelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% GRI BioOutperform Votes4100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in REVB or GRI? 12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 0.1% of Revelation Biosciences shares are held by insiders. Comparatively, 0.1% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate REVB or GRI? GRI Bio has a consensus target price of $115.50, suggesting a potential upside of 7,549.01%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, REVB or GRI? GRI Bio is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$120K-$139.86-0.02GRI BioN/AN/A-$13.04M-$11.56-0.13 Which has more volatility and risk, REVB or GRI? Revelation Biosciences has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.72, meaning that its stock price is 272% less volatile than the S&P 500. Is REVB or GRI more profitable? Revelation Biosciences' return on equity of -193.51% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -193.51% -84.00% GRI Bio N/A -289.05%-165.01% Does the media prefer REVB or GRI? In the previous week, GRI Bio had 8 more articles in the media than Revelation Biosciences. MarketBeat recorded 9 mentions for GRI Bio and 1 mentions for Revelation Biosciences. GRI Bio's average media sentiment score of 0.22 beat Revelation Biosciences' score of -0.50 indicating that GRI Bio is being referred to more favorably in the news media. Company Overall Sentiment Revelation Biosciences Negative GRI Bio Neutral SummaryGRI Bio beats Revelation Biosciences on 9 of the 15 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$793,000.00$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.136.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.295.916.443.97Net Income-$13.04M$142.72M$3.21B$247.65M7 Day Performance13.53%4.38%2.85%1.80%1 Month Performance-76.84%-12.76%-8.64%-6.98%1 Year Performance-98.68%-9.69%11.38%1.34% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.2409 of 5 stars$1.51-1.3%$115.50+7,549.0%-98.7%$793,000.00N/A-0.131Short Interest ↑Analyst RevisionREVBRevelation Biosciences0.4937 of 5 stars$3.48+9.4%N/A-91.0%$3.15MN/A-0.0110Short Interest ↑PALIPalisade Bio3.1234 of 5 stars$0.700.0%$23.00+3,200.8%-89.1%$3.06M$250,000.00-0.0510Short Interest ↓IMCCIM Cannabis0.3467 of 5 stars$1.37flatN/A-55.8%$3.06M$54.03M-0.40340Short Interest ↑ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeMTNBMatinas BiopharmaN/A$0.58+7.4%N/AN/A$2.95M$1.10M-0.1230Gap UpSNPXSynaptogenix2.6898 of 5 stars$2.12-7.0%$14.00+560.4%-55.9%$2.95MN/A-0.204Short Interest ↓Positive NewsGap DownAWHAspira Women's Health2.2068 of 5 stars$0.10+0.9%$5.50+5,512.2%-97.7%$2.92M$9.18M-0.08110Short Interest ↓News CoverageGap UpRDHLRedHill Biopharma0.935 of 5 stars$2.27-5.8%N/A-99.1%$2.91M$3.71M0.00210Short Interest ↓News CoverageGap UpONVOOrganovo0.3547 of 5 stars$1.67+0.3%N/A-87.2%$2.84M$122,000.00-1.9620Short Interest ↑ENSCEnsysce Biosciences0.3048 of 5 stars$1.96-3.4%N/A-81.3%$2.75M$2.23M-0.0710Short Interest ↑News Coverage Related Companies and Tools Related Companies REVB Alternatives PALI Alternatives IMCC Alternatives ARAV Alternatives MTNB Alternatives SNPX Alternatives AWH Alternatives RDHL Alternatives ONVO Alternatives ENSC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRI Stock Free GRI Stock Alerts